Shabir Madhi to Vaccines
This is a "connection" page, showing publications Shabir Madhi has written about Vaccines.
Connection Strength
6,590
-
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date. Paediatr Drugs. 2024 Mar; 26(2):101-112.
Score: 0,802
-
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa. Lancet Infect Dis. 2023 08; 23(8):e288-e300.
Score: 0,776
-
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa. AIDS. 2023 01 01; 37(1):105-112.
Score: 0,743
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
Score: 0,743
-
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply. N Engl J Med. 2021 08 05; 385(6):571-572.
Score: 0,681
-
Special focus on challenges and opportunities for the development and use of vaccines in Africa. Hum Vaccin Immunother. 2018; 14(10):2335-2339.
Score: 0,560
-
Lessons learnt from enrolment and follow up of pregnant women and their infants in clinical trials in South Africa, a low-middle income country. Vaccine. 2015 Nov 25; 33(47):6406-12.
Score: 0,455
-
Vaccine stock-outs: A preventable health facility obstacle contributing to missed vaccinations in South African children. Vaccine. 2025 Jan 25; 45:126583.
Score: 0,215
-
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
Score: 0,194
-
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front Immunol. 2023; 14:1130539.
Score: 0,193
-
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):501-517.
Score: 0,188
-
Innovative vaccine approaches-a Keystone Symposia report. Ann N Y Acad Sci. 2022 May; 1511(1):59-86.
Score: 0,176
-
Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates. Vaccine. 2020 10 07; 38(43):6682-6694.
Score: 0,160
-
Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017 06 05; 35(25):3295-3302.
Score: 0,127
-
The Cape Town Declaration on Vaccines 2012: Unlocking the full potential of vaccines in Africa. Vaccine. 2016 07 19; 34(33):3713-4.
Score: 0,120
-
Advocating for efforts to protect African children, families, and communities from the threat of infectious diseases: report of the First International African Vaccinology Conference. Pan Afr Med J. 2016; 23:53.
Score: 0,117
-
Safety of licensed vaccines in HIV-infected persons: a systematic review protocol. Syst Rev. 2014 Sep 11; 3:101.
Score: 0,106
-
The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative. Pan Afr Med J. 2011; 8:24.
Score: 0,083
-
The National Advisory Group on Immunization (NAGI) of the Republic of South Africa. Vaccine. 2010 Apr 19; 28 Suppl 1:A31-4.
Score: 0,078
-
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Front Immunol. 2020; 11:1282.
Score: 0,040
-
Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. Vaccine. 2017 06 05; 35(25):3303-3308.
Score: 0,032